Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 1
2006 2
2007 3
2008 1
2009 2
2010 2
2011 3
2012 2
2013 5
2014 4
2016 2
2017 10
2018 9
2019 4
2020 6
2021 5
2022 4
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
Phase II Trial of Cisplatin, Gemcitabine, and Intensity-Modulated Radiation Therapy for Locally Advanced Vulvar Squamous Cell Carcinoma: NRG Oncology/GOG Study 279.
Horowitz NS, Deng W, Peterson I, Mannel RS, Thompson S, Lokich E, Myers T, Hanjani P, O'Malley DM, Chung KY, Miller DS, Ueland FR, Dizon DS, Miller A, Mayadev JS, Leath CA 3rd, Monk BJ. Horowitz NS, et al. Among authors: ueland fr. J Clin Oncol. 2024 Apr 4:JCO2302235. doi: 10.1200/JCO.23.02235. Online ahead of print. J Clin Oncol. 2024. PMID: 38574312
Compelling Story of Ovarian Cancer Screening.
Pavlik EJ, van Nagell JR Jr, Dietrich CS 3rd, Ueland FR. Pavlik EJ, et al. Among authors: ueland fr. J Clin Oncol. 2024 Apr 1;42(10):1091-1094. doi: 10.1200/JCO.23.02424. Epub 2024 Feb 2. J Clin Oncol. 2024. PMID: 38306587 No abstract available.
Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study.
Hutchcraft ML, Zhang S, Lin N, Pickarski JC, Belcher EA, Wei S, Bocklage T, Miller RW, Villano JL, Cavnar MJ, Kim J, Arnold SM, Ueland FR, Kolesar JM. Hutchcraft ML, et al. Among authors: ueland fr. JCO Precis Oncol. 2024 Jan;8:e2300266. doi: 10.1200/PO.23.00266. JCO Precis Oncol. 2024. PMID: 38295319 Free PMC article.
Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies.
Wei Y, Erfani S, Schweer D, de Gouvea R, Qadir J, Shi J, Cheng K, Wu D, Craven R, Wu Y, Olivier T, Baldwin LA, Zhou B, Zhou Y, Zhao W, Yang BB, Ueland FR, Yang XH. Wei Y, et al. Among authors: ueland fr. Mol Ther Oncolytics. 2023 Feb 19;28:293-306. doi: 10.1016/j.omto.2023.02.006. eCollection 2023 Mar 16. Mol Ther Oncolytics. 2023. PMID: 36911068 Free PMC article. Review.
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.
Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, O'Malley DM, Street DG, Tewari KS, Bender DP, Morris RT, Lowery WJ, Miller DS, Dewdney SB, Spirtos NM, Lele SB, Guntupalli S, Ueland FR, Glaser GE, Mannel RS, DiSaia PJ. Copeland LJ, et al. Among authors: ueland fr. J Clin Oncol. 2022 Dec 10;40(35):4119-4128. doi: 10.1200/JCO.22.00146. Epub 2022 Jun 27. J Clin Oncol. 2022. PMID: 35759733 Free PMC article. Clinical Trial.
71 results